Skip to Content

LY22-01a

Main Content

Outcomes of autologous HCT and CD19 CAR-T in diffuse large B-cell lymphoma first complete remissiom patients.

Study #: LY22-01a

Study Status: Published

Presentation(s)

2023, ASH (Oral)

Autologous transplant vs. CAR-T therapy in patients with DLBCL treated while in complete remission.

Citation

Shadman M, Ahn KW, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, Ahmed N, Hill B, Hossain NM, Riedell P, Gopal AK, Grover N, Frigault M, Brammer J, Ghosh N, Merryman R, Lazaryan A, Ram R, Hertzberg M, Savani B, Awan F, Khimani F, Ahmed S, Kenkre VP, Ulrickson M, Shah N, Kharfan-Dabaja MA, Herrera A, Sauter C, Hamadani M.

Blood Cancer Journal. 2024, Jul 08: 14(1): 14(1):108. doi: 10.1038/s41408-024-01084-w. Epub 2024, Jul 08. PMCID:PMC11231252.

PubMed

PMID: 38977682

Abstract